|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 nicotinic receptor with unusual pharmacology
Neuronal nicotinic7 subunits have been found in chick and rat skeletal muscle during development and denervation. In the present study, reverse transcriptase-polymerase chain reaction was used to detect
7 subunit mRNA in denervated mouse muscle. To determine whether the
7 subunit forms functional nicotinic acetylcholine receptors (nAChRs) in muscle, choline was used to induce a membrane depolarization because choline has been considered a specific agonist of
7-containing (
7*) nAChRs. We found, however, that choline (3-10 mM) also weakly activates muscle nAChRs. After inhibiting muscle nAChRs with a specific muscle nAChR inhibitor,
-conotoxin GI (
CTxGI), choline was used to activate the
7* nAChRs on muscle selectively. Four weeks after denervation, rapid application of choline (10 mM) elicited a substantial depolarization in the presence of
CTxGI (0.1 µM). This component of the depolarization was never present in denervated muscles obtained from mutant mice lacking the
7 subunit (i.e.
7-null mice). The depolarization component that is resistant to
CTxGI was antagonized by pancuronium (3-10 µM) and by a 4-oxystilbene derivative (F3, 0.1-0.5 µM) at concentrations considered highly specific for
7* nAChRs. Another selective
7 antagonist, methyllycaconitine (0.05-5 µM), did not strongly inhibit this choline-induced depolarization. Furthermore, the choline-sensitive nAChRs showed little desensitization over 10 s of application with choline (10-30 mM). These results indicate that functional
7* nAChRs are significantly present on denervated muscle, and that these receptors display unusual functional and pharmacological characteristics.
This article has been cited by other articles:
![]() |
E. G. Severance, H. Zhang, Y. Cruz, S. Pakhlevaniants, S. H. Hadley, J. Amin, L. Wecker, C. Reed, and J. Cuevas The {alpha}7 Nicotinic Acetylcholine Receptor Subunit Exists in Two Isoforms that Contribute to Functional Ligand-Gated Ion Channels Mol. Pharmacol., September 1, 2004; 66(3): 420 - 429. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |